Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors

References

• Avgoustakis, K. (2004). Pegylated poly (lactide) and poly (lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv 1:321–33
   PubMedGoogle Scholar
• Chan JM, Zhang L, Yuet KP, et al. (2009). PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery. Biomaterials 30:1627–34
   PubMed Web of Science ®Google Scholar
• Ciftci, K, Groves MJ. (1996). Delivery of antitumor compounds to the rat colon: in vitro and in vivo evaluation. Int J Pharm 145:157–64
   Web of Science ®Google Scholar
• Cirstoiu-Hapca A, Buchegger F, Lange N, et al. (2010). Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release 144:324–31
   PubMed Web of Science ®Google Scholar
• Colotta F. (2008). Anticancer drug discovery and development. Targeted therapies in cancer. New York: Springer, 128–43
   Google Scholar
• Dhawale S, Bankar A, Patro M. (2010). Formulation and evaluation porous microspheres of 5-fluorouracil for colon targeting. Int J Pharm Tech Res 2:1112–18
   Google Scholar
• Feng S-S, Chien S. (2003). Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 58:4087–114
   Web of Science ®Google Scholar
• Feng S-S, Zhao L, Zhang Z, et al. (2007). Chemotherapeutic engineering: vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168h in vivo. Chem Eng Sci 62:6641–8
   Web of Science ®Google Scholar
• Holoch PA, Griffith TS. (2009). TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625:63–72
   PubMed Web of Science ®Google Scholar
• Jain A, Gupta Y, Jain SK. (2007). Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci 10:86–128
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK, Ganesh N, et al. (2010). Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomed Nanotechnol Biol Med 6:179–90
   PubMed Web of Science ®Google Scholar
• Jia J, Zhu F, Ma X, et al. (2009). Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8:111–28
   PubMed Web of Science ®Google Scholar
• Krishnaiah Y, Satyanarayana S. (2001). Colon-specific drug delivery systems. Advances in Controlled and Novel Drug Delivery. New Delhi, India: CBS Publishers and Distributors, 89–119
   Google Scholar
• LeBlanc H, Ashkenazi A. (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Different 10:66–75
   PubMed Web of Science ®Google Scholar
• Lehár J, Krueger AS, Avery W, et al. (2009). Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27:659–66
   PubMed Web of Science ®Google Scholar
• Li F, Zhao X, Wang H, et al. (2015). Multiple layer by layer lipid polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models. Adv Funct Mater 25:788–98
   Web of Science ®Google Scholar
• Liu Y, Li K, Pan J, et al. (2010). Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 31:330–8
   PubMed Web of Science ®Google Scholar
• Maya S, Kumar LG, Sarmento B, et al. (2013). Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr Polym 93:661–9
   PubMed Web of Science ®Google Scholar
• Michor F, Iwasa Y, Lengauer C, Nowak MA. (2005). Dynamics of colorectal cancer. Semin Cancer Biol 15:484–93
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Davies FE, Laubach JP, et al. (2011). Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol, 29:1916–23
   PubMed Web of Science ®Google Scholar
• Mohideen B, Ezhilmuthu R, Dhanalekshmi U, Neelakanta Reddy P. (2013). Formulation and in-vitro characterization of gliclazide loaded polymeric nanoparticles. Int J Biol Pharm Res 4:533–40
   Google Scholar
• Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50:161–77
   PubMed Web of Science ®Google Scholar
• Radulovic S, Miller G, Schally AV. (1991). Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res 51:6006–9
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Clark JW, Kemeny NE, et al. (2003). Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 21:2904–11
   PubMed Web of Science ®Google Scholar
• Sengupta S, Eavarone D, Capila I, et al. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568–572
   PubMed Web of Science ®Google Scholar
• Thevenot J, Troutier A-L, David L, et al. (2007). Steric stabilization of lipid/polymer particle assemblies by poly (ethylene glycol)-lipids. Biomacromolecules 8:3651–60
   PubMed Web of Science ®Google Scholar
• Tummala S, Kumar MS, Gowthamarajan K, et al. (2014a). Preparation, physicochemical characterization and in vitro evaluation of oxaliplatin solid lipid nanoparticles for the treatment of colorectal cancer. Indo Am J Pharm Res 4:3579–87
   Google Scholar
• Tummala S, Kumar MS, Prakash A. (2014b). Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J 23:308–14
   PubMed Web of Science ®Google Scholar
• Vivek R, Thangam R, NipunBabu V, et al. (2014). Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy. ACS Appl Mater Interfaces 6:6469–80
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157–63
   PubMed Web of Science ®Google Scholar
• Woodcock J, Griffin JP, Behrman RE. (2011). Development of novel combination therapies. N Engl J Med 364:985–7
   PubMed Web of Science ®Google Scholar
• Zhang L, Chan JM, Gu FX, et al. (2008). self-assembled lipid− polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696–702
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu D, Dong X, et al. (2015). Folate-modified lipid–polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomed 10:2101
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhao B, Jiang H, et al. (2007). Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 123:1–10
   PubMed Web of Science ®Google Scholar
• Zhao X, Li F, Li Y, et al. (2015). Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials 46:13–25
   PubMed Web of Science ®Google Scholar